TapewireFind a company

person · Reporting owner

Francis Knuettel II

Disclosed activity across 14 companies

Tapewire entity
39641
SEC CIK
0001433316

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aqua Metals, Inc.AQMS · Entity 7979Chief Financial OfficerJune 15, 2018June 18, 2018
Beeline Holdings, Inc.BLNE · Entity 7378DirectorSeptember 08, 2026September 10, 2026
CDT Equity Inc.MURF · Entity 1035DirectorFebruary 02, 2022February 11, 2022
Endovia Health Sciences, Inc.SBEV · Entity 8508DirectorJune 08, 2026June 10, 2026
FORUM MARKETS IncATNF · Entity 7020DirectorSeptember 04, 2023September 08, 2023
Innovation1 Biotech Inc.IVBT · Entity 82599Director · Chairman and Interim CEONovember 01, 2024February 04, 2025
OS Therapies IncOSTX · Entity 6950Chief Financial OfficerSeptember 29, 2026October 05, 2026
OceanTech Acquisitions I Corp.OTEC · Entity 112900Chief Financial OfficerMarch 13, 2023April 21, 2023
Relativity Acquisition CorpRACYU · Entity 116251DirectorFebruary 10, 2022February 10, 2022
SCWorx Corp.WORX · Entity 8668DirectorNovember 26, 2019November 29, 2019
SPINDLE, INC.SPDL · Entity 163968DirectorJune 30, 2017July 05, 2017
Tevogen Inc.LGST · Entity 7276Chief Financial OfficerJune 07, 2023June 14, 2023
Unrivaled Brands, Inc.UNRV · Entity 123632Director · CEO and PresidentJune 07, 2021July 12, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aqua Metals, Inc.

Report date June 15, 2018 · Filed June 18, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect162,500 Last balance in matching sequence After 2018-06-18 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2018-06-15 · Purchase · Acquired 2,500 · Balance 157,500

F1: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021.

Row 2 · 2018-06-18 · Purchase · Acquired 5,000 · Balance 162,500

F1: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021.

Beeline Holdings, Inc.

Report date September 08, 2026 · Filed September 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect130,000 Reported balance After 2026-09-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-08 · Grant · Acquired 50,000 · Balance 130,000

F1: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Special Committee of the Board of Directors composed of three non-employee directors. The units shall vest on the earlier of (i) September 8, 2027 or (ii) the disbanding of the Issuer's Special Committee of the Board of Directors, subject to continued service on the Board of Directors of the Company on the applicable vesting date. The grant of restricted stock units was made under the Issuer's Amended and Restated 2025 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Special Committee of the Board of Directors composed of three non-employee directors. The units shall vest on the earlier of (i) September 8, 2027 or (ii) the disbanding of the Issuer's Special Committee of the Board of Directors, subject to continued service on the Board of Directors of the Company on the applicable vesting date. The grant of restricted stock units was made under the Issuer's Amended and Restated 2025 Equity Incentive Plan.

CDT Equity Inc.

Report date February 02, 2022 · Filed February 11, 2022

This filing explicitly reported no securities owned.

Endovia Health Sciences, Inc.

Report date June 08, 2026 · Filed June 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2036-06-08Direct500,000 Reported balance After 2026-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-08 · Grant · Acquired 500,000 · Balance 500,000

F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.

FORUM MARKETS Inc

Report date September 04, 2023 · Filed September 08, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2033-09-04Direct15,000 Reported balance After 2023-09-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-09-04 · Grant · Acquired 15,000 · Balance 15,000

F1: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F2: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.

Common StockSEC Table I · non-derivativeDirect0 Reported balance Holding disclosure · report date 2023-09-04 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F2: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.

Innovation1 Biotech Inc.

Report date November 01, 2024 · Filed February 04, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Series C Senior Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectBy Camden Capital LLCNot disclosed Reported balance Holding disclosure · report date 2024-11-01 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F3: Conversion Price is $0.000000586216897634410.

F1: Reporting Person holds 600,000 shares of Series C Senior Convertible Preferred Stock. Each share of Series C Senior Convertible Preferred Stock is convertible into shares of the Issuer's common stock at any time by dividing the Stated Value of $0.001 by the Conversion Price of $0.000000586216897634410.

F2: Represents shares of Series C Senior Convertible Preferred Stock held by Camden Capital LLC, an entity which the Reporting Person holds voting and investment control.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting Person holds 600,000 shares of Series C Senior Convertible Preferred Stock. Each share of Series C Senior Convertible Preferred Stock is convertible into shares of the Issuer's common stock at any time by dividing the Stated Value of $0.001 by the Conversion Price of $0.000000586216897634410.

F2: Represents shares of Series C Senior Convertible Preferred Stock held by Camden Capital LLC, an entity which the Reporting Person holds voting and investment control.

F3: Conversion Price is $0.000000586216897634410.

OS Therapies Inc

Report date September 29, 2026 · Filed October 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Lara Knuettel Revocable Trust20,000 Reported balance Holding disclosure · report date 2026-09-29 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 20,000

F1: The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

OceanTech Acquisitions I Corp.

Report date March 13, 2023 · Filed April 21, 2023

This filing explicitly reported no securities owned.

Relativity Acquisition Corp

Report date February 10, 2022 · Filed February 10, 2022

This filing explicitly reported no securities owned.

SCWorx Corp.

Report date November 26, 2019 · Filed November 29, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect63,393 Reported balance After 2019-11-26 transaction · row 1
1 source row

Row 1 · 2019-11-26 · Grant · Acquired 50,000 · Balance 63,393

SPINDLE, INC.

Report date June 30, 2017 · Filed July 05, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect530,347 Reported balance After 2017-06-30 transaction · row 1
1 source row

Row 1 · 2017-06-30 · Grant · Acquired 44,118 · Balance 530,347

F1: Shares issued in lieu of cash compensation for Board of Director services.

Filing footnotes · ownership attribution and instrument terms

F1: Shares issued in lieu of cash compensation for Board of Director services.

Tevogen Inc.

Report date June 07, 2023 · Filed June 14, 2023

This filing explicitly reported no securities owned.

Unrivaled Brands, Inc.

Report date June 07, 2021 · Filed July 12, 2021 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,850,000 Reported balance After 2021-06-07 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2021-06-07 · Grant · Acquired 1,500,000 · Balance 1,850,000

F1: The shares of common stock vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date.

F2: This amendment is being filed to reflect the inadvertent omission of shares of common stock already held by the reporting person, which should have been added to the number of shares reported in Table I, Item 5, which number was originally reported as 1,500,000.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date.

F2: This amendment is being filed to reflect the inadvertent omission of shares of common stock already held by the reporting person, which should have been added to the number of shares reported in Table I, Item 5, which number was originally reported as 1,500,000.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Pelthos Therapeutics Inc.

Report date May 22, 2026 · Filed May 26, 2026

Section 16 reporting ended · disclosed 2026-05-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect19,525 Reported balance After 2026-05-22 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-22 · Disposition to issuer · Disposed 13,947 · Balance 19,525

F1: Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F2: The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share ("Common Stock"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs.

Common StockSEC Table I · non-derivativeIndirectBy Lara Knuettel Revocable Trust11,316 Reported balance After 2026-05-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-05-22 · Sale · Disposed 1,500 · Balance 11,316

F3: Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected

F4: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.50 · Expires 2035-07-02Direct59,500 Reported balance After 2026-05-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-05-22 · Grant · Acquired 59,500 · Balance 59,500

F5: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.50 · Expires 2035-07-02Direct0 Reported balance After 2026-05-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-05-22 · Disposition to issuer · Disposed 42,500 · Balance 0

F6: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

Common StockSEC Table I · non-derivativeIndirectBy Camden Capital LLC10,000 Reported balance Holding disclosure · report date 2026-05-22 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 10,000

F4: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F2: The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share ("Common Stock"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs.

F3: Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected

F4: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F5: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

F6: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 08, 2026 Filed Sep 10, 2026 20:10 UTC Beeline Holdings, Inc. BLNE · Entity 7378 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-042160 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Special Committee of the Board of Directors composed of three non-employee directors. The units shall vest on the earlier of (i) September 8, 2027 or (ii) the disbanding of the Issuer's Special Committee of the Board of Directors, subject to continued service on the Board of Directors of the Company on the applicable vesting date. The grant of restricted stock units was made under the Issuer's Amended and Restated 2025 Equity Incentive Plan.

Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:31 UTC Endovia Health Sciences, Inc. SBEV · Entity 8508 GrantStock Options (Right to Buy) · Derivative 500,000 Not disclosed Strike: $0.25 Not disclosed
Disclosure

SEC source: 0001731122-26-000834 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2036-06-08

F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.

F1 · price: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.

F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan, and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:01 UTC Beeline Holdings, Inc. BLNE · Entity 7378 GrantCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-026610 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

F1 · security: The grant of the Issuer's restricted common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The shares of restricted common stock are fully vested and granted under the Issuer's Amended and Restated 2025 Equity Incentive Plan.

Read SEC document
May 22, 2026 Filed May 26, 2026 23:17 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 Disposition to issuerStock Option · Derivative 42,500 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001919246-26-000081 · wk-form4_1779837441.xml · derivative · entry 5

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,500 shares

Expires 2035-07-02

F6 · price: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F6 · derivative.exercise_date: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F6 · derivative.expiration_date: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F6 · balance_after: Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

Read SEC document
May 22, 2026 Filed May 26, 2026 23:17 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantStock Option · Derivative 59,500 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001919246-26-000081 · wk-form4_1779837441.xml · derivative · entry 4

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,500

Underlying: Common Stock · 59,500 shares

Expires 2035-07-02

F5 · price: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

F5 · derivative.exercise_date: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

F5 · balance_after: Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

Read SEC document
May 22, 2026 Filed May 26, 2026 23:17 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 SaleCommon Stock 1,500 $26.84 $40,264.95
Disclosure

SEC source: 0001919246-26-000081 · wk-form4_1779837441.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 11,316

F3 · shares: Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected

F3 · price: Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected

F4 · balance_after: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F4 · ownership.nature: Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC ("Camden"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
May 22, 2026 Filed May 26, 2026 23:17 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 Disposition to issuerCommon Stock 13,947 $0.00 $0.00
Disclosure

SEC source: 0001919246-26-000081 · wk-form4_1779837441.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,525

F1 · shares: Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F1 · price: Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

F2 · balance_after: The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share ("Common Stock"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs.

Read SEC document
December 16, 2025 Filed Dec 17, 2025 21:10 UTC Beeline Holdings, Inc. BLNE · Entity 7378 GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001493152-25-028135 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

F1 · security: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The units shall vest on the earlier of (i) December 16, 2026 or (ii) the delivery of a final report and recommendation by the special committee of the Board of Directors, subject to continued service as a director on the applicable vesting date. The grant of restricted stock units was made under the Issuer's Amended and Restated 2025 Equity Incentive Plan.

F2 · balance_after: Includes 40,000 shares of common stock issuable upon vesting of restricted stock units previously granted on October 2, 2025.

Read SEC document
October 02, 2025 Filed Oct 6, 2025 20:30 UTC Beeline Holdings, Inc. BLNE · Entity 7378 GrantCommon Stock 40,000 $0.00 $0.00
Disclosure

SEC source: 0001493152-25-017080 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

F1 · security: The grant of the Issuer's restricted common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The shares of restricted common stock were granted under the Issuer's Amended and Restated 2025 Equity Incentive Plan. The shares of restricted common stock vest as follows: 10,000 shares shall vest on May 28, 2026 and 30,000 shares shall vest in equal increments annually over three years with the first vesting date on May 28, 2026, subject to continued service as a director as of each applicable vesting date and subject to execution of the Issuer's standard Restricted Stock Agreement.

Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:44 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantStock Option · Derivative 102,000 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001753926-25-001106 · ownership.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,074

Underlying: Common Stock · 102,000 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 102,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and quarterly thereafter in equal installments over a period of two (2) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 102,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and quarterly thereafter in equal installments over a period of two (2) years.

F3 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:44 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantRestricted Stock Units · Derivative 33,472 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001753926-25-001106 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,472

Underlying: Common Stock · 33,472 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 33,472 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 33,472 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

Read SEC document
July 02, 2025 Filed Apr 1, 2026 21:39 UTC Amendment Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantCommon Stock 33,472 $0.00 $0.00
Disclosure

SEC source: 0001919246-26-000039 · wk-form4a_1775079571.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,472

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:04 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 ConversionSeries A Convertible Preferred Stock · Derivative 10,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001753926-25-001077 · ownership.xml · derivative · entry 4

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:04 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 OtherSeries A Convertible Preferred Stock · Derivative 10,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001753926-25-001077 · ownership.xml · derivative · entry 3

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F4 · kind: Acquired in connection with cancellation of promissory note.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:04 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 ConversionCommon Stock 10,000 $10.00 $100,000.00
Disclosure

SEC source: 0001753926-25-001077 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Camden Capital LLC

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Read SEC document
April 11, 2025 Filed Apr 16, 2025 01:30 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantStock Option · Derivative 53,988 Not disclosed Strike: $1.35 Not disclosed
Disclosure

SEC source: 0001753926-25-000643 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,736

Underlying: Common Stock · 53,988 shares

Expires 2035-04-11

F1 · security: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · date: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · shares: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · price: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · derivative.exercise_date: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · derivative.underlying_shares: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · balance_after: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

Read SEC document
September 13, 2024 Filed Sep 16, 2024 20:55 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 PurchaseCommon Stock 3,500 $0.97 $3,395.00
Disclosure

SEC source: 0001753926-24-001576 · ownership.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 547,710

F2 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.94 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Read SEC document
September 12, 2024 Filed Sep 16, 2024 20:55 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 PurchaseCommon Stock 1,700 $0.97 $1,649.00
Disclosure

SEC source: 0001753926-24-001576 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 544,210

F1 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.93 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Read SEC document
September 11, 2024 Filed Sep 12, 2024 21:35 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 PurchaseCommon Stock 5,500 $0.94 $5,170.00
Disclosure

SEC source: 0001753926-24-001570 · ownership.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 542,510

F2 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.89 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Read SEC document
September 10, 2024 Filed Sep 12, 2024 21:35 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 PurchaseCommon Stock 6,500 $0.89 $5,785.00
Disclosure

SEC source: 0001753926-24-001570 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 537,010

F1 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.80 to $0.92 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Read SEC document
June 28, 2024 Filed Jul 2, 2024 21:17 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GiftCommon Stock 15,000 $0.00 $0.00
Disclosure

SEC source: 0001753926-24-001211 · ownership.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 515,510

Read SEC document
June 28, 2024 Filed Jul 2, 2024 21:17 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GiftCommon Stock 5,000 $0.00 $0.00
Disclosure

SEC source: 0001753926-24-001211 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 530,510

Read SEC document
June 14, 2024 Filed Jun 19, 2024 00:01 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantStock Options · Derivative 324,000 Not disclosed Strike: $1.30 Not disclosed
Disclosure

SEC source: 0001753926-24-001129 · ownership.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,778

Underlying: Common Stock · 324,000 shares

Expires 2034-06-14

F3 · price: On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F3 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

Read SEC document
June 14, 2024 Filed Jun 19, 2024 00:01 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantStock Options · Derivative 27,778 Not disclosed Strike: $1.30 Not disclosed
Disclosure

SEC source: 0001753926-24-001129 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · Camden Capital LLC

Disclosed balance after: 52,778

Underlying: Common Stock · 27,778 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $1.30 per share, which were fully vested.

F2 · ownership.nature: The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:17 UTC Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantEmployee Stock Option · Derivative 2,778 Not disclosed Strike: $22.68 Not disclosed
Disclosure

SEC source: 0001753926-24-000376 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · Interim CEO, CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · Camden Capital LLC

Disclosed balance after: 25,001

Underlying: Common Stock · 2,778 shares

Expires 2033-01-10

F2 · price: On January 10, 2023, Camden Capital LLC was granted stock options to purchase 2,778 shares of common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.

F1 · ownership.nature: The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

Read SEC document
February 21, 2024 Filed Jun 19, 2024 00:07 UTC Amendment Pelthos Therapeutics Inc. CHRO · Entity 6798 GrantEmployee Stock Option · Derivative 2,778 Not disclosed Strike: $22.68 Not disclosed
Disclosure

SEC source: 0001753926-24-001139 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · Camden Capital LLC

Disclosed balance after: 25,001

Underlying: Common Stock · 2,778 shares

Expires 2033-01-10

F1 · price: On February 23, 2024, the Reporting Person filed a Form 4 which inadvertently reported that, Camden Capital LLC disposed of 2,778 shares of the Issuer's common stock. In fact, following the grant of stock options to Camden Capital LLC, it acquired 2,778 shares of the Issuer's common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.

F2 · ownership.nature: The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

Read SEC document
September 04, 2023 Filed Sep 8, 2023 20:00 UTC FORUM MARKETS Inc ATNF · Entity 7020 GrantNon-Qualified Stock Option (right to buy) · Derivative 15,000 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001213900-23-075379 · ownership.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-09-04

F1 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F1 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F2 · derivative.exercise_date: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.

Read SEC document
May 19, 2022 Filed May 23, 2022 20:32 UTC FORUM MARKETS Inc ATNF · Entity 7020 GrantNon-Qualified Stock Option (right to buy) · Derivative 21,000 $0.00 Strike: $1.36 $0.00
Disclosure

SEC source: 0001213900-22-028978 · ownership.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2032-05-19

F1 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F1 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F2 · derivative.exercise_date: The Options vest at the rate of 1/39th of such options ratably on a monthly basis over the following 39 months following the grant date, on the last day of each calendar month (beginning on May 31, 2022), subject to the holder's continued service to the Company.

Read SEC document
August 04, 2021 Filed Aug 5, 2021 20:21 UTC FORUM MARKETS Inc ATNF · Entity 7020 GrantNon-Qualified Stock Option (right to buy) · Derivative 79,000 $0.00 Strike: $7.56 $0.00
Disclosure

SEC source: 0001213900-21-040523 · ownership.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,000

Underlying: Common Stock · 79,000 shares

Expires 2031-08-04

F1 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3 promulgated under the Exchange Act.

F1 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3 promulgated under the Exchange Act.

F2 · derivative.exercise_date: The Options vest at the rate of 1/48th of such options ratably on a monthly basis over the following 48 months following the grant date, on the last day of each calendar month (beginning on August 31, 2021), subject to the holder's continued service to the Company.

Read SEC document
July 01, 2021 Filed Jul 12, 2021 21:18 UTC Unrivaled Brands, Inc. UNRV · Entity 123632 GrantWarrant (Right to Buy) · Derivative 192,322 Not disclosed Strike: $0.19 Not disclosed
Disclosure

SEC source: 0001477932-21-004571 · form4.xml · derivative · entry 6

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 192,322

Underlying: Common Stock · 192,322 shares

Expires 2025-06-01

F3 · security: Represents UMBRLA warrants held by the Reporting Person that were assumed by the Issuer in the Merger and converted into warrants exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

F3 · derivative.exercise_price: Represents UMBRLA warrants held by the Reporting Person that were assumed by the Issuer in the Merger and converted into warrants exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

F3 · price: Represents UMBRLA warrants held by the Reporting Person that were assumed by the Issuer in the Merger and converted into warrants exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

Read SEC document
July 01, 2021 Filed Jul 12, 2021 21:18 UTC Unrivaled Brands, Inc. UNRV · Entity 123632 GrantWarrant (Right to Buy) · Derivative 192,322 Not disclosed Strike: $0.01 Not disclosed
Disclosure

SEC source: 0001477932-21-004571 · form4.xml · derivative · entry 5

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 192,322

Underlying: Common Stock · 192,322 shares

Expires 2025-06-01

F3 · security: Represents UMBRLA warrants held by the Reporting Person that were assumed by the Issuer in the Merger and converted into warrants exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

F3 · derivative.exercise_price: Represents UMBRLA warrants held by the Reporting Person that were assumed by the Issuer in the Merger and converted into warrants exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

F3 · price: Represents UMBRLA warrants held by the Reporting Person that were assumed by the Issuer in the Merger and converted into warrants exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

Read SEC document
July 01, 2021 Filed Jul 12, 2021 21:18 UTC Unrivaled Brands, Inc. UNRV · Entity 123632 GrantStock Options · Derivative 769,290 Not disclosed Strike: $0.13 Not disclosed
Disclosure

SEC source: 0001477932-21-004571 · form4.xml · derivative · entry 4

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 769,290

Underlying: Common Stock · 769,290 shares

Expires 2030-11-04

F2 · security: Represents UMBRLA stock options held by the Reporting Person that were assumed by the Issuer in the Merger and converted into options exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

F2 · derivative.exercise_price: Represents UMBRLA stock options held by the Reporting Person that were assumed by the Issuer in the Merger and converted into options exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

F2 · price: Represents UMBRLA stock options held by the Reporting Person that were assumed by the Issuer in the Merger and converted into options exercisable for shares of the Issuer's common stock, as calculated based on the Exchange Ratio. The exercise price was adjusted to reflect the Exchange Ratio.

Read SEC document
July 01, 2021 Filed Jul 12, 2021 21:18 UTC Unrivaled Brands, Inc. UNRV · Entity 123632 GrantCommon Stock 400,000 $0.00 $0.00
Disclosure

SEC source: 0001477932-21-004571 · form4.xml · nonDerivative · entry 3

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,450,000

Read SEC document
July 01, 2021 Filed Jul 12, 2021 21:18 UTC Unrivaled Brands, Inc. UNRV · Entity 123632 GrantCommon Stock 423,456 Not disclosed Not disclosed
Disclosure

SEC source: 0001477932-21-004571 · form4.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 423,456

F1 · shares: Represents shares of the Issuer's common stock acquired by the Reporting Person in connection with the Issuer's acquisition of UMBRLA Inc., a Nevada corporation ("UMBRLA"), pursuant to an Agreement and Plan of Merger, dated as of March 2, 2021, pursuant to which a wholly owned subsidiary of the Issuer merged with and into UMBRLA (the "Merger"), with UMBRLA surviving the Merger as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each share of UMBRLA common stock outstanding and held directly or indirectly by the Reporting Person was converted into the right to receive 1.5386 shares of the Issuer's common stock (the "Exchange Ratio").

F1 · price: Represents shares of the Issuer's common stock acquired by the Reporting Person in connection with the Issuer's acquisition of UMBRLA Inc., a Nevada corporation ("UMBRLA"), pursuant to an Agreement and Plan of Merger, dated as of March 2, 2021, pursuant to which a wholly owned subsidiary of the Issuer merged with and into UMBRLA (the "Merger"), with UMBRLA surviving the Merger as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each share of UMBRLA common stock outstanding and held directly or indirectly by the Reporting Person was converted into the right to receive 1.5386 shares of the Issuer's common stock (the "Exchange Ratio").

Read SEC document
June 18, 2021 Filed Jul 12, 2021 21:18 UTC Unrivaled Brands, Inc. UNRV · Entity 123632 GrantCommon Stock 200,000 $0.00 $0.00
Disclosure

SEC source: 0001477932-21-004571 · form4.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,050,000

Read SEC document
June 07, 2021 Filed Jun 9, 2021 21:53 UTC Unrivaled Brands, Inc. TRTC · Entity 123632 GrantNonqualified Stock Option · Derivative 1,500,000 $0.00 Strike: $0.23 $0.00
Disclosure

SEC source: 0001477932-21-003941 · form4.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

Underlying: Common Stock · 1,500,000 shares

Expires 2031-06-06

F2 · derivative.exercise_date: The nonqualified stock options vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 21:53 UTC Unrivaled Brands, Inc. TRTC · Entity 123632 GrantCommon Stock 1,500,000 $0.23 $350,550.00
Disclosure

SEC source: 0001477932-21-003941 · form4.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

F1 · shares: The shares of common stock vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date.

Read SEC document
June 07, 2021 Filed Jul 12, 2021 21:19 UTC Amendment Unrivaled Brands, Inc. UNRV · Entity 123632 GrantCommon Stock 1,500,000 $0.00 $0.00
Disclosure

SEC source: 0001477932-21-004572 · form4a.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,850,000

F1 · shares: The shares of common stock vest in six equal installments, with the first installment vesting on the June 7, 2021, and the remaining installments vesting on every three-month anniversary thereafter; provided the reporting person is an employee of the issuer on the applicable vesting date.

F2 · balance_after: This amendment is being filed to reflect the inadvertent omission of shares of common stock already held by the reporting person, which should have been added to the number of shares reported in Table I, Item 5, which number was originally reported as 1,500,000.

Read SEC document
December 18, 2020 Filed Dec 22, 2020 16:28 UTC Unrivaled Brands, Inc. TRTC · Entity 123632 GrantNonqualified Stock Option · Derivative 600,000 $0.00 Strike: $0.18 $0.00
Disclosure

SEC source: 0001477932-20-007442 · form4.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: The nonqualified stock options vest in two installments of 300,000 each, with the first installment vesting on March 18, 2021 and the second installment vesting on June 18, 2021.

Read SEC document
December 18, 2020 Filed Dec 22, 2020 16:28 UTC Unrivaled Brands, Inc. TRTC · Entity 123632 GrantCommon Stock 200,000 $0.18 $35,400.00
Disclosure

SEC source: 0001477932-20-007442 · form4.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Read SEC document
November 26, 2019 Filed Nov 29, 2019 21:01 UTC SCWorx Corp. WORX · Entity 8668 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-068686 · tv533692_4.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,393

Read SEC document
February 13, 2019 Filed Feb 15, 2019 16:34 UTC SCWorx Corp. WORX · Entity 8668 GrantCommon Stock Option · Derivative 13,393 Not disclosed Strike: $6.49 Not disclosed
Disclosure

SEC source: 0001144204-19-008583 · tv513916_4.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,393

Underlying: Common Stock · 13,393 shares

Expires 2029-02-13

F2 · price: The options were awarded to the reporting person as compensation for services to be rendered to the issuer through February 12, 2020.

F1 · derivative.exercise_date: The option vests in 4 quarterly installments, commencing ninety days after the grant date.

Read SEC document
June 18, 2018 Filed Jun 18, 2018 22:10 UTC Aqua Metals, Inc. AQMS · Entity 7979 PurchaseCommon Stock 5,000 $2.85 $14,250.00
Disclosure

SEC source: 0001209191-18-038408 · doc4.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,500

F1 · balance_after: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021.

Read SEC document
June 15, 2018 Filed Jun 18, 2018 22:10 UTC Aqua Metals, Inc. AQMS · Entity 7979 PurchaseCommon Stock 2,500 $3.34 $8,341.50
Disclosure

SEC source: 0001209191-18-038408 · doc4.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,500

F1 · balance_after: Includes 150,000 shares underlying restricted stock units ("RSUs") that are not yet vested and deliverable. 50,000 of the RSU's shall vest and be delivered on April 12, 2019, 4,167 of the RSUs shall vest and be delivered each month thereafter, and 4,159 of the RSUs shall vest and be delivered on April 12, 2021.

Read SEC document
June 30, 2017 Filed Jul 5, 2017 18:15 UTC SPINDLE, INC. SPDL · Entity 163968 GrantCommon Stock 44,118 $0.17 $7,500.06
Disclosure

SEC source: 0001393905-17-000201 · primary_doc.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 530,347

F1 · shares: Shares issued in lieu of cash compensation for Board of Director services.

Read SEC document
May 30, 2017 Filed Jun 1, 2017 20:23 UTC SPINDLE, INC. SPDL · Entity 163968 GrantCommon Stock 57,692 $0.13 $7,499.96
Disclosure

SEC source: 0001393905-17-000167 · primary_doc.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 486,229

F1 · shares: Shares issued in lieu of cash compensation for Board of Director services.

Read SEC document
January 10, 2017 Filed Mar 28, 2017 19:18 UTC SPINDLE, INC. SPDL · Entity 163968 GrantCommon Stock 375,000 $0.08 $30,000.00
Disclosure

SEC source: 0001393905-17-000070 · primary_doc.xml · nonDerivative · entry 3

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 428,537

F2 · shares: Shares issued in lieu of cash compensation for Board of Director services.

Read SEC document
December 27, 2016 Filed Mar 28, 2017 19:18 UTC SPINDLE, INC. SPDL · Entity 163968 GiftCommon Stock 100,000 $0.28 $28,000.00
Disclosure

SEC source: 0001393905-17-000070 · primary_doc.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 1

Disclosed balance after: 460,000

F1 · ownership.nature: Indirect beneficial ownership - shares held in entities in which Mr. Knuettel has control.

Read SEC document
December 27, 2016 Filed Mar 28, 2017 19:18 UTC SPINDLE, INC. SPDL · Entity 163968 GiftCommon Stock 148,148 $0.14 $19,999.98
Disclosure

SEC source: 0001393905-17-000070 · primary_doc.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 1

Disclosed balance after: 560,000

F1 · ownership.nature: Indirect beneficial ownership - shares held in entities in which Mr. Knuettel has control.

Read SEC document
September 13, 2016 Filed Sep 13, 2016 21:55 UTC SPINDLE, INC. SPDL · Entity 163968 GrantCommon Stock Warrant · Derivative 37,037 $0.14 Strike: $0.14 $5,000.00
Disclosure

SEC source: 0001393905-16-001040 · primary_doc.xml · derivative · entry 3

Francis Knuettel II · CIK 0001433316 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 37,037

Underlying: SPDL common stock · 37,037 shares

Expires 2019-09-13

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.